Viracta Therapeutics, Inc.
VIRX
Viracta Therapeutics, Inc. ( Viracta or the Company ) is a clinical-stage precision oncology company focused on the treatment and prevention of virus-associated cancers that impact patients worldwide. The association of viruses and cancer has been well characterized, and Viracta's lead program is focused on cancers associated with the Epstein-Barr virus ( EBV ).
Profitability & Returns
Revenue
N/A
Net Income (TTM)
-$43M
▼ -3.8% YoY
Op. Margin
–
ROIC
-89.58%
▼ -18.6pp YoY
Cash Flow & Balance Sheet
FCF (TTM)
-$35M
▼ -12.8% YoY
Op. Cash Flow (TTM)
-$35M
▼ -12.5% YoY
Net Debt
$13M
Cash & Equiv.
$21M
5Y CAGR: -47.7%
Continue Research
SourceComputed from the 10-Q filed 11 Nov 2024, covering the period ending 30 Sept 2024, as reported to the SEC. Data last refreshed 14 Aug 2026. How this is calculated.
Fiscal year ends Dec. Sector medians are approximate S&P 500 benchmarks and update periodically.
Peers
Pharmaceutical Preparations · Pick stocks to compare with VIRX
Spot a number that looks wrong? Check it in VIRX's SEC filings or
Download this analysis as a PDF (Pro)
Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.
Keep analysing VIRX
A free account gives you 10 stocks a day, a watchlist and price alerts.
Already have an account?
Or come back tomorrow. Stocks on your watchlist are always free to view.